GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » ROIC %

AEON Biopharma (AEON Biopharma) ROIC % : 0.00% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. AEON Biopharma's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2023 was 0.00%.

As of today (2024-05-16), AEON Biopharma's WACC % is 5.11%. AEON Biopharma's ROIC % is -58.76% (calculated using TTM income statement data). AEON Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


AEON Biopharma ROIC % Historical Data

The historical data trend for AEON Biopharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEON Biopharma ROIC % Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-298.95 -164.78 -368.15 -106.29 -

AEON Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Sep22 Dec22 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only - -220.89 -82.18 - -

Competitive Comparison of AEON Biopharma's ROIC %

For the Biotechnology subindustry, AEON Biopharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEON Biopharma's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's ROIC % distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's ROIC % falls into.



AEON Biopharma ROIC % Calculation

AEON Biopharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=0 * ( 1 - 0% )/( (73.175 + 1.844)/ 2 )
=0/37.5095
=0.00 %

where

AEON Biopharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2023 is calculated as:

ROIC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=0 * ( 1 - 0% )/( (73.175 + 1.728)/ 2 )
=0/37.4515
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEON Biopharma  (AMEX:AEON) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, AEON Biopharma's WACC % is 5.11%. AEON Biopharma's ROIC % is -58.76% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


AEON Biopharma ROIC % Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


AEON Biopharma (AEON Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4040 MacArthur Boulevard, Suite 260, Newport Beach, CA, USA, 92660
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.
Executives
Strathspey Crown Holdings Group, Llc 10 percent owner 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd 10 percent owner 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson officer: Exec VP, CLO & Corp Secretary 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh officer: Chief Medical Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth director, officer: Chief Executive Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer director C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik 10 percent owner 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds officer: Chief Financial Officer 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano director, 10 percent owner 110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter director C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith officer: Chief Legal Officer&Secretary 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301